Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Marcella Salzano

Marcella Salzano

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca
Marcella Salzano

Marcella Salzano

Marcella Salzano

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Victor Manuel Vargas Blasco, Maria Buti Ferret, Montserrat Gomez Perez, Torrens Buscató, Maria Margarita, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Elena de Sena Fernández, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Cesar Jimenez Hernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Related news

Grup de Malalties Hepàtiques del VHIR

A clinical trial has led to approval of the first drug for advanced fatty liver disease

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Equip projecte ARTEMIs

We study fatty liver and cardiovascular complications with digital twins

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Les Drs. María Martell i Ibane Abasolo

New treatment based on nanoparticles for chronic liver disease

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

See more

Related professionals

Margarita Codinach Creus

Margarita Codinach Creus

Senior researcher
Transfusional Medicine
Read more
Navarro Cantero, Susanna

Navarro Cantero, Susanna

Postdoctoral researcher
Microbiology
Read more
Gisela Gili Serrat

Gisela Gili Serrat

Tècnic de Recerca - Grau Mig
Clinical Research Support Unit (USIC)
Clinical Core Facilities
Core Facilities Area
Read more
Altayo Carulla, Marta

Altayo Carulla, Marta

Research assistant
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.